Androgen antagonists offer a potentially useful treatment for androgen mediated diseases such as: hirsutism, acne, seborrhea, androgenic alopecia, precocious puberty, benign prostatic hyperplasia and prostatic cancer.
The most important therapeutic application of antiandrogens is in the treatment of prostatic cancer and benign prostatic hyperplasia, which are major medical problems in the aging male. Although surgery presently represents the most accepted treatment for prostatic cancer (about 400000 prostectomies performed each year in the USA), there are several other modalities available for the treatment of this disease, such as: inhibition of androgen production by LHRH agonists; inhibition of the conversion of testosterone to dihydrotestosterone by 5a-reductase inhibitors; inhibition of androgen action by androgen receptor antagonists, and several other less common therapies. Since testosterone is converted by the enzyme 5a-reductase into the more active androgen 5a-dihydrotestosterone, which interacts more efficiently with the androgen receptor, this fact indicates very clearly that the logical site of therapeutic intervention should be this last step. 2 In this paper we report the crystal structure of a new steroidal derivative: 17a-acetoxy-6-chloro-16b-methyl-4,6-pregnadiene-3,20-dione. This compound showed high antiandrogenic activity in vitro as well as in vivo and its synthesis has recently been described. 3 The Xray data were collected with graphite monochromatized Cu K a radiation. No absorption correction was applied. Table 1 summarizes the crystal and experimental data.
The molecular structure of the title compound is shown in Fig. 2 . The molecule consists of three six-membered rings and one five-membered ring, all trans fused. According to the torsion angles (Table 2 ) and the puckering parameters values (f 2 , q 2 and Q), the six-membered rings (A and C) occur in envelope and chair conformations, respectively, while ring B and D (f 2 and Q) both occur in an intermediate conformation between half-chair and envelope. 4 The stereochemistry of the title compound is as follows: C9-aH is trans to C10-bCH 3 ; C13-bCH 3 is cis to C17-b(COCH 3 ); and C16-aH is trans to C17-b(COCH 3 ). Bond lengths and 459 ANALYTICAL SCIENCES APRIL 1998, VOL. 14 1998 © The Japan Society for Analytical Chemistry
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Crystal Stucture of 17a-Acetoxy-6-chloro-16b-methyl-4,6-pregnadiene-3,20-dione Manuel SORIANO-GARCÍA*, Simón HERNÁNDEZ-ORTEGA*, Eugene BRATOEFF**, Gregoria FLORES** and Elena RAMÍREZ** -z-1) and C19 … O1 (-x+1, y+1/2, -z-1), 3.425(6) and 3.328(7)Å, respectively. All H-atoms were located via inspection of the difference-Fourier maps and were refined using isotropic temperature factors. Table 3 Bond distances (Å), angles ( o ) and selected torsion angles Fig. 2 The molecular structure of the title compound with the atom labeling. Thermal ellipsoids are drawn at the 50% probability level.
